MOLECULAR CHARACTERISTICS AND CLINICAL ASPECTS OF ALPHA 1-ANTITRYPSIN DEFICIENCY
MOLECULAR CHARACTERISTICS AND CLINICAL ASPECTS OF ALPHA 1-ANTITRYPSIN DEFICIENCY
批准号:
6109231
负责人:
J MOSS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
alpha 1 antitrypsin alpha 1 antitrypsin deficiency asthma bronchodilators clinical research cycloheximide enzyme induction /repression human therapy evaluation immunoglobulin E metabolism disorder chemotherapy molecular pathology patient /disease registry protein degradation respiratory disorder chemotherapy respiratory function
中文摘要
点击翻译按钮获取中文摘要
英文摘要
(a)Alpha1-Antitrypsin (alpha1-AT) deficiency is an
inherited disorder associated with a profound reduction in the
serum alpha1-AT, a major antiprotease of the lower respiratory
tract. Oxidants in the lower respiratory tract reduce the function of
alpha1-AT by oxidizing methionine residue(s) at its active site.
Interaction of alpha1-AT and its major target neutrophil elastase
(NE) is dependent on the conformation of the reactive-site loop
(RSL) of alpha1-AT. We hypothesized that oxidation of the RSL
might alter its stressed conformation and ability to dock and lock
with NE. To evaluate this hypothesis, we compared the
conformation of wild-type (M) and Zalpha1-AT, and their oxidized
counterparts, before and after interaction with NE, using transverse
urea gradient gel and SDS-PAGE. (b)Following intravenous
administration of alpha1-antitrypsin, there was a significant
correlation between the concentrations of functional and antigenic
alpha1-AT in both the epithelial lining fluid (ELF) and serum. The
predicted maximum concentrations of alpha1-AT in ELF was 2.5
muM. It was calculated that a serum concentration of 11.5 muM
alpha1-AT would result in an ELF alpha1-AT concentration of 1.25
muM. The results indicate that serum alpha1-AT concentrations
above 20 muM are not associated with further linear increases in
ELF alpha1-AT concentrations. (c)Individuals with alpha1-AT
deficiency develop severe destructive lung disease much earlier and
undergo more rapid decline in lung function than do the general
population of individuals with chronic obstructive lung disease. We
quantified factors associated with early lung destruction in
individuals with alpha1-AT deficiency. (d)The mutant Z form of alpha1-AT
accounts for more than 95% of all individuals with alpha1-AT
deficiency, an important inherited cause of emphysema and liver
disease. The Zalpha1-AT gene encodes a misfolded form of
alpha1-AT, which polymerizes, accumulates intracellularly, and is
degraded in the rough endoplasmic reticulum (RER) or the
pre-Golgi compartment. Using a Chinese Hamster Ovary (CHO)
cell line permanently transfected with the Zalpha1-AT gene, we
compared the intracellular fate of newly synthesized Zalpha1-AT,
radiolabeled with [S35]-methionine in a pulse-chase fashion, in the
presence of several inhibitors of intracellular degradation.
Cycloheximide and lactacystin prevented intracellular degradation
of Zalpha1-AT. N-acetyl-leucinyl-leucinyl-norleucinal (ALLN),
which inhibits calpains, proteasomes, and lysosomal cysteine
protease, prevented degradation of Zalpha1-AT but did not
significantly alter its secretion. Inhibitors of lysosomal proteolysis,
including ammonium chloride, chloroquine, leupeptin and
colchicine were without effect. In the presence of brefeldin A,
cycloheximide and lactacystin did not prevent Zalpha1-AT
degradation, however, leupeptin and ALLN increased T1/2 of
Zalpha1-AT by 3-and 5-fold, respectively. These observations are
consistent with the existence of at least two intracellular pathways
for Zalpha1-AT degradation. (e)An Italian individual was identified
with asthma, emphysema, and a very low level of serum alpha1-AT.
DNA sequencing demonstrated the Mprocida deficiency allele and a
novel null allele QOtrastevere (c654 G A, W194Z), a nonsense
mutation near the intron 2 (IVS2) splice acceptor site. A Chinese
hamster ovary cell line was permanently transfected with
QOtrastevere or normal Malpha1-AT with and without IVS2. The
nonsense mutation was associated with moderately reduced
alpha1-AT mRNA regardless of IVS2, supporting a
translational-translocation model as the cause of reduced
alpha1-AT mRNA rather than a nuclear scanning model.
Pulse-chase studies followed by immunoprecipitation demonstrated
an endoplasmic reticulum-retained 31-kDa QOtrastevere
alpha1-AT, which was rapidly degraded; retention and degradation
appeared to be the major reasons for the absence of secreted
alpha1-AT. (f)In smokers, unopposed protease activity may lead to
emphysema by unrestricted activity of neutrophil elastase (NE).
Alpha1-Antitrypsin inhibitor (alpha1-AT), the main inhibitor of NE,
contains critical methionines which, if oxidized, block its anti-NE
activity. Hydrogen peroxide is a critical component of cigarette
smoke that inactivates alpha1-AT. To establish the molecular basis
of oxidative inactivation, we studied the sites oxidized by hydrogen
peroxide in alpha1-AT. Using simultaneous Edman sequencing of
peptides produced by treatment with cyanogen bromide to identify
all methionines in alpha1-AT, it was observed that two of the nine
methionines were particularly susceptible to oxidation. One was
methionine 358, whose oxidation is known to cause loss of anti-NE
activity. The other methionine, 351, was as susceptible to oxidation
as methionine 358. Its oxidation also resulted in loss of anti-NE
activity. Methionine 226 was less readily oxidized and none of the
other six methionines was susceptible to attack by hydrogen
peroxide. Under experimental conditions formation of an
alpha1-AT-NE complex protected both methionines from
oxidation, while methionine 226 was not protected, consistent with
methionines 351 and 358 being located at or near the site of
inhibitor interaction. The susceptibility to oxidation of all nine
methionines correlates well with the extent of their exposure on the
surface of the molecule. Oxidative inactivation of alpha1-AT
provides a mechanism for regulation of its activity at sites of
inflammation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHARACTERIZATION OF MAMMALIAN ADP-RIBOSLYTRANSFERASES
-
批准号:2576748
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
CHARACTERIZATION OF THE PATHOGENESIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
-
批准号:2441409
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3857979
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
ROLE OF NITRIC OXIDE IN THE PATHOGENESIS OF LUNG DISEASE
-
批准号:2576802
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
ADP-RIBOSYLATION CYCLES
-
批准号:6162671
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
MOLECULAR CHARACTERISTICS AND CLINICAL ASPECTS OF ALPHA 1-ANTITRYPSIN DEFICIENCY
-
批准号:6162714
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
MOLECULAR CHARACTERISTICS AND CLINICAL ASPECTS OF ALPHA 1-ANTITRYPSIN DEFICIENCY
-
批准号:2576803
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
PATHOGENESIS AND THERAPY OF PULMONARY FIBROSIS
-
批准号:6109234
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
CHARACTERIZATION OF MAMMALIAN ADP-RIBOSLYTRANSFERASES
-
批准号:6162666
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
ROLE OF NITRIC OXIDE IN THE PATHOGENESIS OF LUNG DISEASE
-
批准号:6162713
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3843260
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
ADP-RIBOSYLATION CYCLES
-
批准号:2576753
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
CHARACTERIZATION OF THE PATHOGENESIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
-
批准号:6162716
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3919996
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3878894
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
TRANSDUCIN GTPASE--GENES FOR GTP-BINDING PROTEINS
-
批准号:4694497
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE MECHANISMS
-
批准号:4694491
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3779503
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3942780
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
REGULATION OF CYCLIC NUCLEOTIDE METABOLISM
-
批准号:3966535
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J MOSS
-
依托单位:
海外基金